- Home
- INTR vs TNGX Comparison
INTR vs TNGX Comparison
Compare INTR & TNGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | INTR | TNGX |
|---|---|---|
| Founded | 1994 | 2014 |
| Country | Brazil | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.7B | 2.9B |
| IPO Year | 2021 | 2020 |
Fundamental Metrics
Financial Performance| Metric | INTR | TNGX |
|---|---|---|
| Price | $5.67 | $20.22 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 10 |
| Target Price | $10.00 | ★ $21.78 |
| AVG Volume (30 Days) | ★ 9.1M | 2.5M |
| Earning Date | 05-11-2026 | 05-08-2026 |
| Dividend Yield | ★ 1.51% | N/A |
| EPS Growth | N/A | ★ 26.89 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $62,384,000.00 |
| Revenue This Year | $84.07 | N/A |
| Revenue Next Year | $18.26 | N/A |
| P/E Ratio | $16.39 | ★ N/A |
| Revenue Growth | N/A | ★ 48.29 |
| 52 Week Low | $5.64 | $3.77 |
| 52 Week High | $10.36 | $28.41 |
Technical Indicators
Market Signals| Indicator | INTR | TNGX |
|---|---|---|
| Relative Strength Index (RSI) | 32.80 | 42.30 |
| Support Level | $5.64 | $6.77 |
| Resistance Level | $8.73 | $22.01 |
| Average True Range (ATR) | 0.26 | 1.47 |
| MACD | 0.01 | -0.06 |
| Stochastic Oscillator | 6.06 | 6.95 |
Price Performance
Historical ComparisonAbout INTR Inter & Co. Inc.
Inter & Co Inc operates as a digital bank. The company's segment includes Banking & Spending; Investments; Insurance Brokerage; and Inter Shop. It generates maximum revenue from the Banking & Spending segment which comprises a wide range of banking products and services, such as checking accounts, cards, deposits, loans and advances, and other services, which are available to the clients by means of Inters mobile application.
About TNGX Tango Therapeutics Inc.
Tango Therapeutics Inc is a biotechnology company. It is dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. It is currently developing two MTA-cooperative PRMT5 inhibitors; TNG462 for non-CNS cancers, including pancreatic and lung cancer, and TNG456, a next-generation, brain-penetrant PRMT5 inhibitor, for CNS cancers, including GBM. Its pipeline products are PRMT5 and CoREST.